...
首页> 外文期刊>Materials science & engineering >A multilayer hollow nanocarrier for pulmonary co-drug delivery of methotrexate and doxorubicin in the form of dry powder inhalation formulation
【24h】

A multilayer hollow nanocarrier for pulmonary co-drug delivery of methotrexate and doxorubicin in the form of dry powder inhalation formulation

机译:多层中空纳米载体,以干粉吸入制剂的形式用于肺部共同给药甲氨蝶呤和阿霉素的药物

获取原文
获取原文并翻译 | 示例
           

摘要

Lung cancer is the number one cause of cancer deaths in the global population and remains difficult to treat mainly because of the absence of targeted drug delivery stages and restrictions related with delivery of drugs to deep lung tissues. The aim of the present study was to develop a noninvasive, patient-convenient formulation for the targeted delivery of chemotherapeutics to cancer cells located in the deep lung tissue. A PEGylated paramagnetic hollow-nanosphere was fabricated, fully characterized and used as a nanocarrier for pulmonary co-delivery of Doxorubicin (DOX) and Methotrexate (MTX). In first step, magnetic-silica nanoparticles were synthesized and then coated with amino/acrylate groups and derivatized with polyethylene glycol (PEG). Finally, silica was removed to provide hollow structured nanoparticles. The biocompatibility of blank carriers and the efficiency of MTX-DOX-loaded carriers were also approved by MTT assay and DAPI staining. The aerosolization performance of nanoparticles embedded microspheres were assessed by next generation impactor. The almost natural zeta potential and obvious decrease in silica content observed by EDX and removal of intense silica characteristic peak at FTIR analyses approved the successful removal of silica layer and preparation of hollow-nanospheres. The successful PEGylation of multilayer magnetic hollow-nanospheres catalyzed by boric acid was confirmed by presence of amide groups in FTIR spectra. The developed polymeric nanoparticle showed quite appropriate loading capacity for both DOX and MTX (48%) because of designing adequate negatively and positively charged sites for both drugs. The cytotoxicity assays proved the safety of blank nanoparticles and efficacy of drugs-loaded nanoparticles on lung cancer A549 cell lines. The developed dry powder inhalation formulation of nanoparticles showed appropriate aerosolization performance (fine particle fraction around 22%). It was concluded that these outcomes may open the potentials for efficient pulmonary co-delivery of MTX and DOX to the carcinogenic tissues.
机译:肺癌是全球人口中导致癌症死亡的第一大原因,并且仍然难以治疗,主要是因为缺乏靶向的药物输送阶段以及与向深部肺组织输送药物有关的限制。本研究的目的是开发一种无创,方便患者的制剂,用于将化学治疗药物靶向递送至位于肺深部组织的癌细胞。制备了聚乙二醇化的顺磁性空心纳米球,对其进行了充分表征,并将其用作纳米载体用于阿霉素(DOX)和甲氨蝶呤(MTX)的肺部共同递送。第一步,合成磁性二氧化硅纳米粒子,然后用氨基/丙烯酸酯基团涂覆并用聚乙二醇(PEG)衍生化。最后,除去二氧化硅以提供中空结构的纳米颗粒。通过MTT测定和DAPI染色也证实了空白载体的生物相容性和载有MTX-DOX的载体的效率。通过下一代撞击器评估了嵌入纳米颗粒的微球的雾化性能。用EDX观察到几乎天然的ζ电位和二氧化硅含量的明显降低以及在FTIR分析中除去强烈的二氧化硅特征峰,证明成功除去了二氧化硅层并制备了中空纳米球。硼酸催化多层磁性空心纳米球的成功聚乙二醇化是通过FTIR光谱中酰胺基的存在来证实的。由于为两种药物设计了足够的带负电荷和带正电荷的位点,因此开发的聚合物纳米颗粒对DOX和MTX均显示了相当合适的负载能力(48%)。细胞毒性试验证明了空白纳米颗粒的安全性和载药纳米颗粒对肺癌A549细胞株的有效性。已开发的纳米颗粒干粉吸入制剂显示出适当的雾化性能(细颗粒分数约为22%)。结论是,这些结果可能为将MTX和DOX有效地肺部共同递送至致癌组织打开了可能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号